Who are nivolumab plus relatlimab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PD-1 / PD-L1 monoclonal antibody, PD1/PDL1 inhibitor, Full course of PD-1/PD-L1 blockades, atezolizumab or durvalumab, TQB3473, TQB2303.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nivolumab-plus-relatlimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

nivolumab plus relatlimab — Competitive Intelligence Brief

nivolumab plus relatlimab (nivolumab plus relatlimab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-1, LAG-3 Oncology Biologic Live · refreshed every 30 min

Target snapshot

nivolumab plus relatlimab (nivolumab plus relatlimab) — Immatics US, Inc.. Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nivolumab plus relatlimab TARGET	nivolumab plus relatlimab	Immatics US, Inc.	phase 3	PD-1/PD-L1 inhibitor	PD-1, LAG-3
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
PD1/PDL1 inhibitor	PD1/PDL1 inhibitor	Second Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Full course of PD-1/PD-L1 blockades	Full course of PD-1/PD-L1 blockades	Sun Yat-sen University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and PD-L1
atezolizumab or durvalumab	atezolizumab or durvalumab	Anhui Shi, MD	phase 3	PD-1/PD-L1 inhibitor	PD-L1
TQB3473	TQB3473	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
AstraZeneca · 2 drugs in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
EMD Serono · 1 drug in this class
EMS · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
Cellvax Therapeutics Inc · 1 drug in this class
Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nivolumab plus relatlimab — Competitive Intelligence Brief. https://druglandscape.com/ci/nivolumab-plus-relatlimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab